Strategic Plans to Promote Head and Neck Cancer Translational Research Within the Radiation Therapy Oncology Group: A Report From the Translational Research Program

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 2 SUPPL., 2007, Pages

  Chung, Christine H ^a   Wong, Stuart ^b   Ang, K Kian ^c   Hammond, Elizabeth H ^d   Dicker, Adam P ^e   Harari, Paul M ^f   Le, Quynh Thu ^g  

^a Radiation Therapy Oncology Group   (United States)

^b Head and Neck Cancer Subcommittee   (United States)

^c Head and Neck Cancer Subcommittee   (United States)

^d Translational Research Program   (United States)

^e RADIATION THERAPY ONCOLOGY GROUP   (United States)

^f Translational Research Program   (United States)

^g STANFORD UNIVERSITY   (United States)

Author keywords

Biomarkers; Funding; Head and neck cancer; RTOG; Translational research

Indexed keywords

BIOMARKERS; DIAGNOSIS; GENES; PATIENT TREATMENT; TOXICITY;

CANCER BIOLOGY; CLINICAL TRIALS; HEAD AND NECK CANCER; HUMAN GENOME PROJECT; SYSTEMS BIOLOGY; TRANSLATIONAL RESEARCH;

ONCOLOGY;

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PANITUMUMAB; VANDETANIB;

ARTICLE; BIOINFORMATICS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA MICROARRAY; DNA SEQUENCE; EPSTEIN BARR VIRUS; FUNDING; GENOMICS; HEAD AND NECK CANCER; HEALTH PROGRAM; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; METASTASIS; MONOTHERAPY; NASOPHARYNX CARCINOMA; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; STRATEGIC PLANNING; WART VIRUS;

BIOMEDICAL RESEARCH; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH SUPPORT AS TOPIC; TISSUE BANKS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548476013     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.04.090     Document Type: Article

References (86)

1. Cancer Facts and Figures 2003 (2003), American Cancer Society, Atlanta, GA
2. Ang K.K., Andratschke N.H., and Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 58 (2004) 959-965
3. Joyce A.R., and Palsson B.O. The model organism as a system: Integrating "omics" data sets. Nat Rev Mol Cell Biol 7 (2006) 198-210
4. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
5. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
6. Hammond E., Berkey B.A., Fu K.K., et al. P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: A clinical/laboratory correlative analysis of RTOG-9003. Int J Radiat Oncol Biol Phys 57 (2003) 683-692
7. Raben D., Bianco C., Milas L., et al. Targeted therapies and radiation for the treatment of head and neck cancer: Are we making progress?. Semin Radiat Oncol 14 (2004) 139-152
8. Grandis J., Melhem M., Gooding W., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
9. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
10. Burtness B., Goldwasser M.A., Flood W., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
11. Baselga J., Trigo J.M., Bourhis J., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5568-5577
12. Herbst R.S., Arquette M., Shin D.M., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5578-5587
13. Cohen E.E.W., Rosen F., Stadler W.M., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 (2003) 1980-1987
14. Soulieres D., Senzer N.N., Vokes E.E., et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
15. Cohen E.E., Lingen M.W., Martin L.E., et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11 (2005) 8105-8108
16. Chung C.H., Ely K., McGavran L., et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24 (2006) 4170-4176
17. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
18. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung Cancer: Correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
19. Camp E.R., Summy J., Bauer T.W., et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11 (2005) 397-405
20. Ono M., and Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12 (2006) 7242-7251
21. Benavente S., Huang S., Armstrong E., et al. Establishment of acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in human tumor cell lines. [Abstract]. Proc Am Assoc Cancer Res 45 (2004) 1230
22. Koizumi F., Shimoyama T., Taguchi F., et al. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 116 (2005) 36-44
23. Benavente S., Armstrong E., Hsu K.-T., et al. Array-based identification of genes and proteins associated with resistance to EGFR inhibitors. [Abstract]. Proc Am Assoc Cancer Res 47 (2006) 294
24. Arnoletti J.P., Buchsbaum D.J., Huang Z.Q., et al. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J Gastrointest Surg 8 (2004) 960-970
25. Buck E., Eyzaguirre A., Haley J.D., et al. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 5 (2006) 2051-2059
26. Sergina N.V., Rausch M., Wang D., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445 (2007) 437-441
27. Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 (2000) 709-720
28. Gillison M.L., and Shah K.V. Human papillomavirus-associated head and neck squamous cell carcinoma: Mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 13 (2001) 183-188
29. Mork J., Lie A.K., Glattre E., et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344 (2001) 1125-1131
30. Dai M., Clifford G.M., le Calvez F., et al. Human papillomavirus type 16 and TP53 mutation in oral cancer: Matched analysis of the IARC multicenter study. Cancer Res 64 (2004) 468-471
31. Dahlgren L., Mellin H., Wangsa D., et al. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer 107 (2003) 244-249
32. Li G., and Sturgis E.M. The role of human papillomavirus in squamous carcinoma of the head and neck. Curr Oncol Rep 8 (2006) 130-139
33. Slebos R.J., Yi Y., Ely K., et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 12 (2006) 701-709
34. Schwartz S.R., Yueh B., McDougall J.K., et al. Human papillomavirus infection and survival in oral squamous cell cancer: A population-based study. Otolaryngol Head Neck Surg 125 (2001) 1-9
35. Lindel K., Beer K.T., Laissue J., et al. Human papillomavirus positive squamous cell carcinoma of the oropharynx: A radiosensitive subgroup of head and neck carcinoma. Cancer 92 (2001) 805-813
36. Andl T., Kahn T., Pfuhl A., et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58 (1998) 5-13
37. Erler J.T., Bennewith K.L., Nicolau M., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006) 1222-1226
38. Rich J.N., Hans C., Jones B., et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65 (2005) 4051-4058
39. Chung C.H., Parker J.S., Karaca G., et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5 (2004) 489-500
40. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
41. van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
42. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
43. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
44. Beer D.G., Kardia S.L., Huang C.C., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8 (2002) 816-824
45. Bhattacharjee A., Richards W.G., Staunton J., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98 (2001) 13790-13795
46. Yamagata N., Shyr Y., Yanagisawa K., et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res 9 (2003) 4695-4704
47. Eschrich S., Yang I., Bloom G., et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23 (2005) 3526-3535
48. Dhanasekaran S.M., Barrette T.R., Ghosh D., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826
49. Lossos I.S., Czerwinski D.K., Alizadeh A.A., et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350 (2004) 1828-1837
50. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. [Comment]. N Engl J Med 346 (2002) 1937-1947
51. Valk P.J., Verhaak R.G., Beijen M.A., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350 (2004) 1617-1628
52. Bullinger L., Dohner K., Bair E., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350 (2004) 1605-1616
53. Glinsky G.V., Berezovska O., and Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115 (2005) 1503-1521
54. Chung C.H., Levy S., Chaurand P., et al. Genomics and proteomics: Emerging technologies in clinical cancer research. Crit Rev Oncol Hematol 61 (2007) 1-25
55. Belbin T.J., Singh B., Barber I., et al. Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res 62 (2002) 1184-1190
56. Ginos M.A., Page G.P., Michalowicz B.S., et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 64 (2004) 55-63
57. El-Naggar A.K., Kim H.W., Clayman G.L., et al. Differential expression profiling of head and neck squamous carcinoma: Significance in their phenotypic and biological classification. Oncogene 21 (2002) 8206-8219
58. Al Moustafa A.E., Alaoui-Jamali M.A., Batist G., et al. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 21 (2002) 2634-2640
59. Cromer A., Carles A., Millon R., et al. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23 (2004) 2484-2498
60. Chung C.H., Parker J.S., Ely K., et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-{kappa}B signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 66 (2006) 8210-8218
61. Jacquemier J., Ginestier C., Rougemont J., et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65 (2005) 767-779
62. Torres-Roca J.F., Eschrich S., Zhao H., et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 65 (2005) 7169-7176
63. Chan A.T., Lo Y.M., Zee B., et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94 (2002) 1614-1619
64. Lin J.C., Wang W.Y., Chen K.Y., et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350 (2004) 2461-2470
65. Le Q.T., Jones C.D., Yau T.K., et al. A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res 11 (2005) 5700-5707
66. Le Q.T., Sutphin P.D., Raychaudhuri S., et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9 (2003) 59-67
67. Overgaard J., Eriksen J.G., Nordsmark M., et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764
68. Dunst J., Stadler P., Becker A., et al. Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 177 (2001) 469-473
69. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12 (2001) 375-391
70. Yoshino O., Osuga Y., Koga K., et al. Upregulation of interleukin-8 by hypoxia in human ovaries. Am J Reprod Immunol 50 (2003) 286-290
71. Dornhofer N., Spong S., Bennewith K., et al. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 66 (2006) 5816-5827
72. Gunaratnam L., Morley M., Franovic A., et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 278 (2003) 44966-44974
73. De Schutter H., Landuyt W., Verbeken E., et al. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 5 (2005) 42
74. Fredriksson S., Gullberg M., Jarvius J., et al. Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol 20 (2002) 473-477
75. Gullberg M., Gustafsdottir S.M., Schallmeiner E., et al. Cytokine detection by antibody-based proximity ligation. Proc Natl Acad Sci U S A 101 (2004) 8420-8424
76. Hardenbol P., Baner J., Jain M., et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 21 (2003) 673-678
77. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2 (2002) 795-803
78. Kyzas P.A., Stefanou D., and Agnantis N.J. COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Mod Pathol 18 (2005) 153-160
79. Viloria-Petit A., Crombet T., Jothy S., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61 (2001) 5090-5101
80. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
81. Sandler A., Gray R., Brahmer J., et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial-E4599. [Abstract]. Proc Am Soc Clin Oncol 23 (2005)
82. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
83. Seiwert T., Haraf D., Cohen E., et al. A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC). [Abstract]. Proc Am Soc Clin Oncol 24 (2006)
84. Vokes E., Cohen E., Mauer A., et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). [Abstract]. Proc Am Soc Clin Oncol (2005) 23
85. Marsh S., and McLeod H.L. Cancer pharmacogenetics. Br J Cancer 90 (2004) 8-11
86. Beecher C. The human metabolome. Metabolic profiling: Its role in biomarker discovery and gene function analysis (2003), Kluwer Academic Publishers, Boston, MA 311-319